June 01, 2017
HSV-1 enhances the energy metabolism of human MSCs to promote virus infection
Today Future Science Group announces the publication of an article in Future Virology that reveals how herpes simplex virus type-1 (HSV-1) infection influences energy metabolism of human umbilical cord-derived mesenchymal stem cells (UCMSCs).
Mesenchymal stem cells (MSC’s) are regularly used in clinical treatment; however, their use comes at a high risk of contamination, particularly from viral infections in stem cell transplantation patients.
Previous studies have demonstrated how viral infections can alter the energy metabolism of host cells. Due to the biological importance of MSC’s, research into the interactions between these cells and viruses has gained great attention.
In this study researchers set to identify the effect of HSV-1 on human UCMSC’s in an ex vivo experimental model. They discovered that HSV-1 infection rapidly activated mitochondrial biogenesis, increased glucose consumption, oxidative phosphorylation and glycolysis of UCMSC’s. Further experiments also demonstrated that treatment with a metabolism antagonist significantly inhibited HSV-1 proliferation.
“This study demonstrates, for the first time, that HSV-1 infection affects the energy metabolism process of UCMSCs. Treatment with the appropriate metabolism antagonists might improve the safety and efficacy of clinical stem cell therapies”, explained the authors (Institute of Biomedicine, College of Life Science & Technology, Jinan University, China).
The article is available to read at: http://www.futuremedicine.com/doi/full/10.2217/fvl-2017-0038
About Future Virology
Launched in 2006, the journal Future Virology (https://www.futuremedicine.com/loi/fvl) is part of the Future Medicine journal collection. Future Virology (impact factor: 0.886) features the latest updates in virology, infectious disease and immunology analysis, with an international Editorial Board headed by Editor-in-Chief Mark Wainberg (McGill AIDS Centre, Canada).
About Future Science Group
Founded in 2001, Future Science Group (FSG) is a progressive publisher focused on breakthrough medical, biotechnological, and scientific research. FSG’s portfolio includes two imprints, Future Science and Future Medicine. In addition to this core publishing business FSG develops specialist eCommunities. Key titles and sites include Bioanalysis Zone, Epigenomics, Nanomedicine and the award-winning Regenerative Medicine.
The aim of FSG is to service the advancement of clinical practice and drug research by enhancing the efficiency of communications among clinicians, researchers and decision-makers, and by providing innovative solutions to their information needs. This is achieved through a customer-centric approach, use of new technologies, products that deliver value-for-money and uncompromisingly high standards.